Genomic Expression is featured at the Emerging Medical Technologies Spotlight Meeting today

Aug. 11, 2010 - PRLog -- Genomic Expression, Inc. is featured at the Emerging Medical Technologies  Spotlight Meeting today, where Gitte Pedersen, CEO delivered a 10-minute CEO presentation  along with summary of development status, fundraising/partnering needs, market, technology, business strategy, management team, financial status, sales forecasts, and IP position (http://www.lifescienceintelligence.com/emt-spotlight-2010-08.php).
Genomic Expression is launching a first generation Digital Array to key universities and corporations and anticipates generating revenue in 2010.  
The Digital Array is 10-100 times less expensive to manufacture then current analog arrays and the same product has infinite applications whereas the current analog arrays are custom designed to a specific problem.
Genomic Expression’s Digital Array is merging the ease of use of the array platform and the quality content that so far has only been provided by utilizing expensive and cumbersome sequencing machines.
Genomic Expression’s management and advisors have extensive R&D, start-up, big pharma, diagnostic, deal, board, VC and fundraising experience and worked in companies such as Pfizer, Novo Nordisk, Lundbeck, Chr. Hansen, Ortho Clinical Diagnostics, Eastman Kodak and hold academic positions at Karolinska, The Danish Cancer Society, Copenhagen University MIT and University of California.
The Emerging Medical Technologies Spotlight Meeting is attended by LSI’s members including the top Medical Device Investment Firms and the most active dealmakers and acquirers (http://www.lifescienceintelligence.com/partner-list.php).

# # #

Genomic Expression (GEx™) is an early stage company head quartered in New York developing next generation genomics products for personalized medicine. The DATA™ platform abbreviates the process of developing diagnostics for Personalized Medicine.